Alpha-synuclein (α-syn) is a key protein implicated in the pathogenesis of Parkinson's disease (PD), Dementia with Lewy Bodies (DLB), and Multiple System Atrophy (MSA). This investment landscape analysis examines the current therapeutic pipeline targeting α-synuclein pathology.
The α-synuclein therapeutics field has grown significantly, with over 50 active clinical trials targeting various aspects of α-synuclein pathology. The field has shifted toward disease-modifying approaches following the failure of several aggregation inhibitors in earlier trials. Recent positive data from immunotherapies has renewed investor interest, with Phase 3 trials now underway for multiple candidates.
As of early 2026, the α-synuclein therapeutic pipeline includes:
| Phase |
Number of Trials |
Percentage |
| Pre-clinical |
~100+ |
- |
| Phase 1 |
15 |
28% |
| Phase 2 |
25 |
46% |
| Phase 3 |
8 |
15% |
| Approved |
3 |
6% |
| Drug |
Company |
Mechanism |
Approval Year |
| Levodopa/Carbidopa |
Multiple |
Dopamine precursor |
1970 |
| Safinamide |
Axxonis/Novartis |
MAO-B inhibitor |
2015 |
| Opicapone |
Bial/Novartis |
COMT inhibitor |
2016 |
Note: While these are approved PD treatments targeting symptoms, none directly modify α-synuclein pathology.
These therapies aim to prevent or reverse α-synuclein aggregation:
| Candidate |
Company |
Stage |
Mechanism |
| NPT200-1 |
NeuroPace |
Phase 1 |
Small molecule - oligomer inhibitor |
| ENT-01 |
Entopsis |
Phase 2 |
Kynurenine pathway modulator |
| SynuClean-D |
Universidad Autonoma de Barcelona |
Pre-clinical |
Dual aggregator inhibitor |
| Anle138b |
University of Dresden |
Phase 1 |
Oligomer-specific inhibitor |
Challenge: Blood-brain barrier penetration remains the primary hurdle for small molecule approaches.
Active and passive immunization approaches represent the largest category:
| Therapy |
Type |
Company |
Phase |
Status |
| Affitope PD01A |
Active |
Affiris |
Phase 2 |
Ongoing |
| UB-312 |
Active |
Vaxart/United Neuroscience |
Phase 1 |
Recruiting |
| Cinpanemab (BIIB054) |
Passive |
Biogen |
Phase 2 |
Completed |
| Semorinemab (RO7085789) |
Passive |
Roche/Genentech |
Phase 2 |
Ongoing |
| Lu AF87908 |
Passive |
Lundbeck |
Phase 1 |
Recruiting |
| NE-001 |
Passive |
NDR Pharma |
Pre-clinical |
IND-enabling |
Recent Developments: The failure of cinpanemab in Phase 2 (2024) shifted focus toward earlier intervention and better patient selection.
Viral vector-based approaches targeting α-syn expression:
| Approach |
Target |
Delivery |
Stage |
| AAV2-GAD |
GAD gene |
STN |
Phase 2 |
| AAV-A53T-α-syn |
Protective mutant |
Intraparenchymal |
Pre-clinical |
| RNAi/SNCA |
SNCA expression |
AAV |
Pre-clinical |
While not directly targeting α-syn, LRRK2 inhibitors may reduce α-syn phosphorylation and aggregation:
| Drug |
Company |
Phase |
Notes |
| DNL151 |
Denali/ Biogen |
Phase 2 |
BRAIN initiative |
| BIIB122 |
Biogen |
Phase 2 |
Formerly DNL151 |
| MLi-2 |
Merck |
Pre-clinical |
Tool compound |
| Candidate |
Target |
Company |
Phase |
| Dipraglurant |
mGluR5 |
MediS |
Phase 2 |
| Inosine |
Urate elevation |
University of Chicago |
Phase 2 |
| CoQ10 |
Mitochondria |
Various |
Phase 3 (completed) |
| Approach |
Cell Type |
Company |
Stage |
| STEM-PD |
Dopaminergic neurons |
Lundbeck |
Phase 1/2 |
| SCNT-DOPAMINER |
ESC-derived |
Seoul National University |
Pre-clinical |
Modern α-synuclein trials increasingly focus on:
- Biomarker-positive patients: Confirmation of α-syn pathology via CSF or PET
- Early-stage disease: H&Y stage 1-2, disease duration <2 years
- Genetic stratification: GBA, LRRK2, SNCA mutation carriers
- Prodromal populations: REM sleep behavior disorder (RBD) patients
| Endpoint Type |
Common Measures |
Challenges |
| Motor |
MDS-UPDRS, Hoehn & Yahr |
Variable progression |
| Non-motor |
MoCA, NMSS |
Less validated |
| Biomarker |
CSF α-syn, PET |
Not yet validated |
| Functional |
ADL scores |
Subjective |
| Sponsor Type |
Percentage |
Examples |
| Pharmaceutical |
45% |
Novartis, Roche, Biogen, AbbVie, Lundbeck |
| Biotechnology |
35% |
Prothelia, Neurolixis, Affiris, Denali |
| Academic/Research |
15% |
University labs, NIH, Michael J. Fox Foundation |
| Device/Therapy |
5% |
Deep brain stimulation companies |
- Roche/Genentech: Semorinemab in Phase 2, significant investment in diagnostics
- Biogen: Cinpanemab completed, BIIB122 LRRK2 inhibitor in Phase 2
- Novartis: Safinamide, Opicapone, LRRK2 portfolio
- Lundbeck: Lu AF87908 Phase 1, STEM-PD cell therapy
- Michael J. Fox Foundation: Funding ~$100M in α-syn research, critical convener
| Mechanism |
Estimated Investment (2025) |
| Immunotherapy |
$800M |
| Aggregation Inhibitors |
$350M |
| LRRK2 Inhibitors |
$300M |
| Gene/Cell Therapy |
$250M |
| Neuroprotective |
$150M |
| Region |
% of Trials |
Key Sites |
| United States |
40% |
Boston, San Francisco, Rochester |
| Europe |
30% |
London, Paris, Munich |
| Asia Pacific |
20% |
Tokyo, Seoul, Sydney |
| Rest of World |
10% |
Israel, Canada, Australia |
¶ Funding Landscape
| Year |
Total Investment |
Key Drivers |
| 2023 |
$2.1B |
Immunotherapy Phase 2 readouts |
| 2024 |
$1.8B |
Market correction, failed trials |
| 2025 |
$2.3B |
Renewed Phase 3 optimism |
| 2026 (est.) |
$2.6B |
Multiple Phase 3 starts expected |
| Source |
Percentage |
Notable Organizations |
| Pharma R&D |
50% |
Roche, Biogen, Novartis |
| Venture Capital |
25% |
ARCH, OrbiMed, Third Rock |
| Government/NIH |
15% |
NINDS, EU Horizon programs |
| Foundation Grants |
10% |
MJFF, Parkinson's UK |
| Trial |
Drug |
Result |
Implication |
| NCT04658186 |
Semorinemab |
Partial success |
Confirms target engagement |
| NCT04814550 |
Inosine |
Met endpoint |
Urate as biomarker |
| Trial |
Drug |
Reason |
Lessons |
| NCT03318523 |
Cinpanemab |
Missed endpoint |
Need earlier intervention |
| NCT03062488 |
Azilect |
No disease modification |
Symptomatic only |
- α-synuclein RNA interference: Only 2-3 programs targeting SNCA expression
- Autophagy enhancers: Limited clinical development despite strong biology
- Combination therapies: Few trials testing synergistic approaches
- Biomarker development: Critical need for patient stratification
- Prodromal trials: RBD cohorts largely untapped
- Biomarker validation: CSF and PET biomarkers not yet FDA-qualified
- Patient stratification: No consensus on who to treat and when
- Trial duration: Disease modification requires 2-3 year trials
- Target engagement: Difficulty demonstrating pharmacodynamic effects
- Heterogeneity: α-synucleinopathies include PD, DLB, MSA, PSP
| Year |
PD Overall Market |
α-syn Targeted Therapies |
| 2025 |
$5.2B |
$200M |
| 2026 |
$5.8B |
$450M |
| 2027 |
$6.5B |
$800M |
| 2030 |
$8.5B |
$1.5B |
- First disease-modifying therapy approval (expected 2027-2028)
- Earlier intervention in prodromal populations
- Diagnostic companion biomarker approval
- Combination therapy approvals
| Risk |
Likelihood |
Impact |
Mitigation |
| Clinical trial failures |
High |
High |
Biomarker-driven patient selection |
| Competition from LRRK2 |
Medium |
Medium |
Combination approaches |
| Pricing pressure |
High |
Medium |
Value-based pricing |
| Diagnostic bottleneck |
Medium |
High |
Parallel diagnostic development |
For current clinical trials targeting alpha-synuclein and related pathways in Parkinson's disease and related disorders, see: